Production (Stage)
Proto Script Pharmaceutical Corp.
PSCR
$0.0003
$0.000.00%
OTC PK
| 09/30/2017 | 06/30/2017 | 03/31/2017 | 12/31/2016 | 09/30/2016 | |
|---|---|---|---|---|---|
| Revenue | -32.95% | -30.09% | -36.03% | -10.50% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.95% | -30.09% | -36.03% | -10.50% | -- |
| Cost of Revenue | 68.62% | 117.54% | 101.42% | 19.87% | -- |
| Gross Profit | -53.22% | -54.97% | -55.37% | -18.71% | -- |
| SG&A Expenses | 78.52% | 61.77% | 34.75% | 2.58% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.85% | 69.37% | 43.05% | 5.73% | -- |
| Operating Income | -8,847.75% | -1,795.93% | -7,891.21% | -103.27% | -- |
| Income Before Tax | -66,658.73% | -17,826.11% | -74,041.51% | -4,846.83% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -66,658.73% | -17,826.11% | -74,041.51% | -4,846.83% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66,658.73% | -17,826.11% | -74,041.51% | -4,846.83% | -- |
| EBIT | -8,847.75% | -1,795.93% | -7,891.21% | -103.27% | -- |
| EBITDA | -3,442.36% | -8,510.78% | -1,189.77% | -314.29% | -- |
| EPS Basic | -2,413.33% | -1,776.47% | -8,866.67% | -206.67% | -- |
| Normalized Basic EPS | -1,077.78% | -600.00% | -3,800.00% | 67.39% | -- |
| EPS Diluted | -2,413.33% | -1,776.47% | -8,866.67% | -206.67% | -- |
| Normalized Diluted EPS | -1,077.78% | -600.00% | -3,800.00% | 67.39% | -- |
| Average Basic Shares Outstanding | -39.72% | -7.74% | -8.38% | 58.63% | -- |
| Average Diluted Shares Outstanding | -39.72% | -7.74% | -8.38% | 58.63% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |